Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | PLK1 | P53350 | 2/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6598073 | 0.99 | ALDH1A1 (0.38) | ALDH1A1LMNARAB9ASMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL1194041 | 0.92 | ALDH1A1 (0.38) | ALDH1A1LMNARAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6595709 | 0.91 | ALDH1A1 (0.38) | ALDH1A1LMNARAB9ASMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL1193915 | 0.87 | KMT2A (0.35) | ALDH1A1LMNARAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6596187 | 0.86 | KMT2A (0.35) | ALDH1A1LMNARAB9ASMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL6599921 | 0.83 | LMNA (0.34) | ALDH1A1LMNAKDM4EL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL1194171 | 0.83 | ACHE (0.32) | ALDH1A1LMNAKDM4EACHE | |
| SCHEMBL6599195 | 0.82 | ACHE (0.32) | ALDH1A1LMNAKDM4EACHE | |
| Hydrochloric Acid SCHEMBL1193715 | 0.80 | MAPT (0.34) | ALDH1A1LMNARAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6596219 | 0.79 | MAPT (0.35) | ALDH1A1LMNARAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034378-A1 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. | TORRENT PHARMACEUTICALS LTD. (IN) | 2011-02-10 | — | — | US | claimed |
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2007-07-19 | — | — | US | claimed |
| US-7223777-B2 | Compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2007-05-29 | — | — | US | claimed |
| CN-1259316-C | Heterocyclic compounds for age-related and diabetic vascular system complications | TORRENTAU PHARMACEUTICAL LTD (IN) | 2006-06-14 | — | — | CN | claimed |
| EP-1373263-B1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | TORRENT PHARMACEUTICALS LTD (IN) | 2004-10-27 | — | — | EP | claimed |
| CN-1498217-A | Heterocyclic compounds for aging-related and diabetic vascular complications | ������˹ҩƷ��˾ | 2004-05-19 | — | — | CN | claimed |
| WO-2002085897-A9 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | SANKARANARAYANAN ALANGUDI (IN) | 2004-04-01 | — | — | WO | claimed |
| EP-1373263-A1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | Torrent Pharmaceuticals Ltd (IN) | 2004-01-02 | — | — | EP | claimed |
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-03-06 | — | — | US | claimed |
| WO-2002085897-A1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | SANKARANARAYANAN ALANGUDI (IN) | 2002-10-31 | — | — | WO | claimed |
| US-20110034378-A1 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. | TORRENT PHARMACEUTICALS LTD. (IN) | 2011-02-10 | — | — | US | disclosed |
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2007-07-19 | — | — | US | disclosed |
| US-7223777-B2 | Compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2007-05-29 | — | — | US | disclosed |
| CN-1259316-C | Heterocyclic compounds for age-related and diabetic vascular system complications | TORRENTAU PHARMACEUTICAL LTD (IN) | 2006-06-14 | — | — | CN | disclosed |
| EP-1373263-B1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | TORRENT PHARMACEUTICALS LTD (IN) | 2004-10-27 | — | — | EP | disclosed |
| CN-1498217-A | Heterocyclic compounds for aging-related and diabetic vascular complications | ������˹ҩƷ��˾ | 2004-05-19 | — | — | CN | disclosed |
| WO-2002085897-A9 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | SANKARANARAYANAN ALANGUDI (IN) | 2004-04-01 | — | — | WO | disclosed |
| EP-1373263-A1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | Torrent Pharmaceuticals Ltd (IN) | 2004-01-02 | — | — | EP | disclosed |
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-03-06 | — | — | US | disclosed |
| WO-2002085897-A1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | SANKARANARAYANAN ALANGUDI (IN) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | AGER, GLA, F12 | ACHE 136/4885ALDH1A1 132/4885LMNA 641/4885 |
| US-20110034378-A1 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. | AGER, F12, DPP4 | ACHE 1371/4885ALDH1A1 528/4885LMNA 818/4885 |
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | AGER, GLA, F12 | ACHE 101/4885ALDH1A1 226/4885LMNA 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.